Lv3
390 积分 2023-03-10 加入
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
3天前
待确认
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
3天前
已关闭
Cancer incidence and mortality in China, 2022
4个月前
已完结
Blocking PCSK9 enhances immune checkpoint therapy
5个月前
已完结
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis
5个月前
已完结
Chemotherapy in stage-IV NSCLC
5个月前
已完结
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
7个月前
已完结
Cancer incidence and mortality in China, 2022
9个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
10个月前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
10个月前
已完结
皖公网安备34019202002308
